Physician profile
William Brian Ward
NPI 1427031780
$5,280.41
in general payments reported to CMS, 2019-2025
26 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $256 · 2021: $445 · 2022: $764 · 2023: $979 · 2024: $941 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161 · Education: $65.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.92 |
| Education | $65.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $605.34 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $546.12 | 2019-2023 | Krystexxa |
| Amgen INC. | $525.83 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $479.07 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $466.11 | 2021-2024 | |
| Akebia Therapeutics INC | $376.05 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $336.02 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $277.99 | 2019-2025 | |
| Outset Medical INC | $244.47 | 2025 | |
| Vifor Pharma, INC. | $227.56 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $197.55 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $147.09 | 2019 | |
| Mallinckrodt Hospital Products INC. | $146.14 | 2023-2025 | Terlivaz, Acthar |
| Glaxosmithkline, LLC. | $142.15 | 2019-2024 | Jesduvroq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.06 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $80.29 | 2024 | |
| Novo Nordisk INC | $68.31 | 2023-2024 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $63.34 | 2022-2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $52.84 | 2020-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.64 | 2023-2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $46.05 | 2023-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $28.42 | 2022-2023 | Lupkynis |
| Daiichi Sankyo INC. | $23.66 | 2024 | Injectafer |
| Ani Pharmaceuticals, INC. | $23.58 | 2022 | |
| Lilly USA, LLC | $22.27 | 2025 | Jardiance |
| Lundbeck LLC | $17.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.